DDInter676 DDInter1435
Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including,, and, for example.[A177271, F4498] Its efficacy is considered similar to other medications within the PPI class including,,,, and. Esomeprazole is the s-isomer of, which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as, without any significant differences between the two compounds _in vitro_. Esome
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Esomeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Esomeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Esomeprazole {u} (Compound) binds {v} (Gene) ATP4A
Esomeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
Esomeprazole {u} (Compound) palliates {v} (Disease) prostate cancer
Esomeprazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Esomeprazole {u} (Compound) downregulates {v} (Gene) TRAPPC3
Esomeprazole {u} (Compound) causes {v} (Side Effect) Muscle spasms
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Choline salicylate
Esomeprazole (Compound) resembles Lansoprazole (Compound)
Esomeprazole (Compound) resembles Omeprazole (Compound)
Esomeprazole (Compound) treats Barrett's esophagus (Disease)
Esomeprazole (Compound) binds ATP4A (Gene)
Esomeprazole (Compound) upregulates TIPARP (Gene)
Esomeprazole (Compound) palliates prostate cancer (Disease)
Esomeprazole (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Esomeprazole (Compound) downregulates TRAPPC3 (Gene)
Esomeprazole (Compound) causes Muscle spasms (Side Effect)
Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Choline salicylate